Bharat Biotech has completed the enrolment of 25,800 volunteers for the phase 3 clinical trials of Covaxin, its COVID-19 vaccine.

The vaccine has completed two of the three required trial phases. The third one, testing for efficacy, began in November. The company is setting up four vaccine manufacturing facilities with a combined capacity of 700 million doses per year, the company’s chairman Dr Krishna Ella said on Monday. "We have four facilities coming up. We are planning around 200 million doses (per year) in Hyderabad, 500 million doses in other cities. By 2021, we will have 700 million doses capacity... As we speak we have 20 million doses," he stated… (NDTV, January 7, 2021)